***Background.*** Increasing use of the central venous catheter has become associated with catheter-related bloodstream infection due to rapidly growing non-tuberculous mycobacteria, especially in immunocompromised patients. We identified an outbreak of central venous catheter-related bloodstream infection due to *Mycobacterium mucobgenicum and Mycobatereium canariasense* among patients with hematologic disorders during a 5-month period.

***Methods.*** An outbreak investigation and infection control protocol were performed at a hematology ward at a Japanese tertiary care center. We conducted a retrospective chart review and environmental investigation to identify the source of rapidly growing non-tuberculous mycobacteria and patients\' outcome.

***Results.*** A total of five patients with bloodstream infection due to rapidly growing non-tuberculous mycobacteria were identified: three patients with acute myeloid leukemia, and one patient with acute lymphocytic leukemia developed a blood culture positive for *M. mucogenicum*. In addition one patient with aplastic anemia developed a blood culture positive for *M. canariasense*. The majority of patients received cord blood transplantation prior to developing bloodstream infection. All central venous catheters in patients with bloodstream infection due to *mycobacterium* spp. were removed. These patients promptly defervesced after catheter removal and were successfully managed without antimicrobial therapy. With extensive environmental examination, *M. mucogenicum* and *M. canariasense*were subsequently identified from water supplies in the hematology ward. We confirmed identification of the isolates from the bloodstream infection and environmental sources based on 16SrRNA gene sequencing.

***Conclusion.*** The source of rapidly growing non-tubeculous mycobacteria in outbreak of bloodstream infection likely stemmed from the hematology ward tap water supply. Awareness of emerging catheter-related bloodstream infection due to *mycobacterium* spp. should be emphasized, especially in immunocompromised patients and treatment strategies should continue to be discussed.
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